Plasma Metanephrines in Patients With Cyanotic and Acyanotic Congenital Heart Disease

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04891081

Enrollment

Registered

2021-05-18

Start date

2019-11-01

Completion date

2021-06-09

Last updated

2021-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acyanotic Congenital Heart Disease, Cyanotic Congenital Heart Disease, Paraganglioma, Pheochromocytoma

Brief summary

The aim of our study is to compare plasma metanephrines in patients with cyanotic and acyanotic congenital heart disease and possible association with chronic hypoxic stress.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patients with congenital heart disease attending regular follow up

Exclusion criteria

* missing main data in medical documentation

Design outcomes

Primary

Measure	Time frame	Description
Plasma metanephrine level	baseline, one point of time in a cross-sectional study	Level of plasma metanephrine
Plasma normetanephrine level	baseline, one point of time in a cross-sectional study	Level of plasma normetanephrine

Secondary

Measure	Time frame	Description
Hypoxemia	baseline, one point of time in a cross-sectional study	Length of hypoxemia presence in years

Countries

Slovenia

Contacts

Primary ContactMojca Jensterle, MD, PhD

mojca.jensterlesever@kclj.si03861 522 35 64

Outcome results